Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05719467
Other study ID # 235247
Secondary ID
Status Recruiting
Phase Phase 3
First received
Last updated
Start date January 3, 2023
Est. completion date December 31, 2027

Study information

Verified date April 2024
Source Oslo University Hospital
Contact Trond M Michelsen, MD PhD
Phone +4723070000
Email trmi1@ous-hf.no
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Over the past years, the rates of labor induction have increased steadily, and at present more than one in four births occurs after induced labor in Norway. There is evidence that several groups of women benefit from labor induction, including those with preeclampsia (1), postdate pregnancy, diabetes, a large-for-gestational-age fetus, gestational diabetes, prelabor rupture of membranes at term, preterm prelabor rupture of membranes, twin pregnancy and intrahepatic cholestasis of pregnancy. At the same time, induction of labor is an independent risk factor for adverse obstetric outcomes, including cesarean section, operative vaginal delivery, chorioamnionitis, labor dystocia, prolonged labor, uterine rupture, and neonatal pH < 7.10. A recent Norwegian nationwide clinical practice pilot evaluation demonstrated that the rate of intervention was high, and that as many as 44% of women with labor induction experienced operative delivery. Given that induction of labor is a common procedure (15 000 women per year in Norway) and increases risk of several major obstetric complications, interventions that may reduce operative births and facilitate safe deliveries are highly warranted. Bicarbonate and butylscopolamine bromide have been used in smaller studies in order to shorten labor. The medications seem to be safe with a low frequency of adverse events. The rationale of the present study is therefore to assess the efficacy of oral bicarbonate and intravenous butylscopolamine bromide on facilitating spontaneous (non-operative) delivery in pregnant female participants with induction of labor.


Recruitment information / eligibility

Status Recruiting
Enrollment 3000
Est. completion date December 31, 2027
Est. primary completion date January 31, 2025
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Female
Age group 18 Years to 50 Years
Eligibility Inclusion Criteria: 1. Participant must be between 18 and 50 years of age at the time of signing the informed consent. 2. Participants who are female, pregnant, nulliparous and at or above 37 weeks of gestation 3. Participants who fulfill hospital criteria for induction of labor, and where a decision to induce labor has been made 4. Participants carrying a fetus in vertex position 5. Capable of giving signed informed consent as described in Appendix 1, which includes compliance with the requirements and restrictions listed in the informed consent form (ICF). Exclusion Criteria: 1. Multiple gestation 2. Elective cesarean section 3. Spontaneous start of labor 4. Known maternal intestinal stenosis, ileus or megacolon 5. Persisting maternal tachycardia (heart rate > 130 beats per minute) >30 minutes continuously. 6. Known maternal myasthenia gravis 7. Persisting fetal tachycardia (fetal heart rate baseline > 170 beats per minute) >30 minutes continuously. 8. Maternal hypersensitivity to any of the ingredients in IMP (butylscopolamine bromide, bicarbonate or sodium chloride) 9. Women with heart disease who are under surveillance with heart rate monitoring during labor 10. Known fetal heart disease or known fetal malformations in the gastrointestinal system 11. Untreated maternal glaucoma 12. Maternal electrolyte disturbance: severe hyponatremia, severe hypokalemia 13. Maternal moderate/severe kidney failure (stage III-V: glomerulus filtration rate <59 ml/minute/1.73m2 ) 14. Maternal elevated serum creatinine (>90umol/L) 15. Maternal elevated Alanine Aminotransferase (ALAT) >100 U/L. Participation can still be considered for participants with ALAT >100 U/L if explained by obstetric cholestasis or HELLP syndrome.

Study Design


Intervention

Drug:
Buscopan 20 MG/ML Injectable Solution
1 mL intravenously
Sodium bicarbonate
4 g orally
Placebo
4g orally
Nacl 0.9%
1 mL intravenously

Locations

Country Name City State
Norway Akershus University Hospital Lørenskog
Norway Oslo University Hospital Rikshospitalet Oslo
Norway Oslo University Hospital Ullevål Oslo
Norway Stavanger University Hospital Stavanger
Norway The University Hospital of North Norway Tromsø

Sponsors (1)

Lead Sponsor Collaborator
Oslo University Hospital

Country where clinical trial is conducted

Norway, 

Outcome

Type Measure Description Time frame Safety issue
Primary Spontaneous vs operative birth Number of participants with operative birth as compared to spontaneous birth Through study completion, an average of one week
See also
  Status Clinical Trial Phase
Completed NCT05017974 - Research on Improving Sleep During Pregnancy N/A
Completed NCT03284515 - Vaccination In Pregnancy Gene Signature: VIP Signature Study
Recruiting NCT05969795 - Comparison of Live Birth Rate in Natural Cycle Single Euploid FET Versus Without Luteal Phase Support Phase 1
Recruiting NCT06051201 - Innovation for Small-scale Experiments: ReceptIVFity Test N/A
Recruiting NCT04828382 - Prospective Study of Pregnancy in Women With Cystic Fibrosis
Enrolling by invitation NCT04527926 - STEPuP: Prenatal Provider Education and Training to Improve Medication-assisted Treatment Use During Pregnancy N/A
Recruiting NCT04278651 - Early Antenatal Support for Iron Deficiency Anemia Phase 4
Recruiting NCT04405700 - Measuring Adverse Pregnancy and Newborn Congenital Outcomes
Recruiting NCT06258902 - Odevixibat Pregnancy and Lactation Surveillance Program: A Study to Evaluate the Safety of Odevixibat During Pregnancy and/or Lactation
Completed NCT05487196 - Effectiveness of Clonidine, Dexmedetomidine, and Fentanyl Adjuncts for Labor Epidural Analgesia Phase 2
Completed NCT03750968 - Lutein & Zeaxanthin in Pregnancy - Carotenoid Supplementation During Pregnancy: Ocular and Systemic Effects Phase 2
Enrolling by invitation NCT06127277 - Next4You: A Fully Mobile Relationships Based Program for Youth in Foster Care N/A
Completed NCT05897697 - Assessing Women's Preferences for Postpartum Thromboprophylaxis: the Prefer-Postpartum Study
Recruiting NCT05899101 - The Impact of Opioid and Cannabis Exposure on Fetal Growth
Completed NCT05502510 - Assessing the Effectiveness and Efficacy of the MyHealthyPregnancy Application
Completed NCT04296396 - Opioid Prescription After Cesarean Trial Phase 3
Not yet recruiting NCT06069856 - Multiple Micronutrient Supplementation (MMS) IFA- Iron Dose Acceptability Crossover Trial Phase 3
Not yet recruiting NCT06069869 - Multiple Micronutrient Supplementation (MMS) Iron Dose Acceptability Crossover Trial Phase 3
Not yet recruiting NCT06079918 - Multiple Micronutrient Supplementation for Maternal Anemia Prevention in Tanzania Phase 3
Not yet recruiting NCT06163651 - Evaluating a One-Year Version of the Parent-Child Assistance Program N/A